Olorinab (APD371), a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2, reduces colitis-induced acute and chronic visceral hypersensitivity in rodents.

Publication Year: 2022

DOI:
10.1097/j.pain.0000000000002314

PMCID:
PMC8675055

PMID:
33863856

Journal Information

Full Title: Pain

Abbreviation: Pain

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Psychophysiology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article."

Evidence found in paper:

"Medical writing support was provided by ApotheCom (San Francisco, CA) and was funded by Arena Pharmaceuticals. S.M. Brierley was supported by a National Health and Medical Research Council of Australia (NHMRC) R.D. Wright Biomedical Research Fellowship (APP1126378) and by NHMRC Australia Project Grants (APP1139366 and APP1140297). J. Castro is funded by an NHMRC Australia Ideas Grant (APP1181448). A.M. Harrington is funded by an ARC Discovery Project (DP180101395)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025